CBIO Insider Receives 9,023 Stock Options Expiring in 2035

Rhea-AI Filing Summary

Form 4 highlights: On 06/23/2025, director Alexandra Balcom received a stock option for 9,023 ordinary shares of GlycoMimetics Inc. (ticker indicated as CBIO) at an exercise price of $15.30 per share. The option vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, subject to her continued board service, and expires on 23 Jun 2035.

No other equity transactions—purchases, sales, or additional share ownership—were disclosed. After the grant, Ms. Balcom beneficially owns 9,023 derivative securities directly; Table I for non-derivative holdings is blank, suggesting she held no common shares before the grant.

Implications for investors: The award is part of routine director compensation and does not represent an open-market purchase; therefore, it does not immediately affect the share count or cash flow. The filing adds a modest potential dilution—approximately 9 k shares—once the option is exercised. While small relative to total shares outstanding, the grant aligns the director’s long-term incentives with shareholder value appreciation.

Insights

Financial Analyst

TL;DR: Routine director option grant; limited immediate impact, minor potential dilution, standard alignment of incentives.

The Form 4 reports a single grant of 9,023 stock options to director Alexandra Balcom at $15.30, vesting within one year or at the next AGM. No open-market activity is involved, so there is no direct signal of insider confidence through cash deployment. The option adds only a fraction of a percent to the company’s fully diluted share count, implying negligible valuation impact. From a governance standpoint, the straightforward vesting schedule keeps director interests tied to share performance over the next decade. I classify the development as neutral for valuation and liquidity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O/ CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.3	06/23/2025		A		9,023		(1)	06/23/2035	Ordinary Shares	9,023	$0.00	9,023	D

Explanation of Responses:

1. This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

	/s/ Barbara Bispham, as attorney-in-fact for Alexandra Balcom	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.